Intercell and Merck: Strategic alliance to develop monoclonal antibodies for the treatment of Staphylococcus aureus infections

15-May-2006

Intercell AG announced that it has entered into a strategic partnership with Merck & Co., Inc. to develop human monoclonal antibodies against severe infections caused by Staphylococcus aureus, a bacterium, that causes severe hospitalacquired infections and has become increasingly resistant to a variety of antibiotics.

Under the terms of an agreement signed in May 2004, Merck has exercised an option to receive worldwide rights to develop and commercialize antibodies directed against proprietary antigens that have been detected by Intercell's Antigen Identification Program (AIP®). This technology identifies antibacterial targets. Pursuant to the agreement, Merck Inc. is responsible for subsequent preclinical and clinical development, registration and marketing of the product.

Intercell is entitled to an option exercise fee and additional milestone payments. Furthermore, Intercell will receive royalties on future sales of the product. There are no further costs involved for Intercell.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous